Sakar Healthcare Ltd

Sakar Healthcare Limited's investor presentation for Q2 and H1FY27 highlights strong financial performance, with revenue, EBITDA, and PAT showing significant year-over-year growth. The company executed 69 oncology product contracts and has 45 commercial discussions ongoing. It has expanded its global oncology presence, with 33 tech transfer projects underway and 11 site variations approved in stringent markets. The company has shared 351 dossiers globally, with 22 receiving Marketing Authorizations across Europe, Latin America, APAC, and Canada. Sakar has developed 21 APIs, with 8 commercialized and 2 CEP applications approved. The consolidated financials show revenue growth of 52% YoY in Q2FY27, EBITDA up 114%, and PAT up 149%. The balance sheet reflects increased assets and equity, with a debt-to-equity ratio of 0.2 in FY26. The company emphasizes its integrated API-FDF manufacturing model, green chemistry practices, and expansion into oncology as key growth drivers. Strategic initiatives include diversification into oncology products, technology transfer, and partnerships for global market access. The presentation also outlines future goals, including increasing overseas contracts to over 100 and dossier approvals to 300 within two years.

The presentation emphasizes strong financial growth, strategic expansion, and operational advancements, reflecting a positive outlook on the company's performance and future prospects.